CRIS vs. SGMO, SABS, XFOR, AGEN, ALVR, BLUE, PLX, VIGL, ATRA, and PASG
Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Sangamo Therapeutics (SGMO), SAB Biotherapeutics (SABS), X4 Pharmaceuticals (XFOR), Agenus (AGEN), AlloVir (ALVR), bluebird bio (BLUE), Protalix BioTherapeutics (PLX), Vigil Neuroscience (VIGL), Atara Biotherapeutics (ATRA), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 3 articles in the media. Curis' average media sentiment score of 0.20 beat Sangamo Therapeutics' score of -0.10 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Curis received 246 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Curis an outperform vote while only 62.66% of users gave Sangamo Therapeutics an outperform vote.
Curis has lower revenue, but higher earnings than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics has a net margin of -146.30% compared to Sangamo Therapeutics' net margin of -473.04%. Curis' return on equity of -82.17% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, meaning that its stock price is 259% more volatile than the S&P 500.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sangamo Therapeutics presently has a consensus target price of $5.67, suggesting a potential upside of 948.61%. Curis has a consensus target price of $37.33, suggesting a potential upside of 131.02%. Given Curis' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Curis.
Summary
Sangamo Therapeutics and Curis tied by winning 8 of the 16 factors compared between the two stocks.
Get Curis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
